Neuraltus raises $10M for Lou Gehrig's work; Roche submits vismodegib app; PTC banks $5M grant;

 @FierceBiotech: More than 1/3 of clinical trials conducted by pharma cos. are now being outsourced, says a Kalorama report. Story  | Follow @FierceBiotech

 @JohnCFierce: Proposed "model" plan would restrict portions of sensitive studies to "legitimate scientists." Via WSJNews | Follow@JohnCFierce

 @RyanMFierce: Seattle's biotech scene lacked startup activity in '11 but didn't want for M&A action. via @ldtimmerman. Article  | Follow@RyanMFierce

> Palo Alto, CA-based Neuraltus has reportedly raised close to $10 million in a new round. The biotech is developing a treatment for Lou Gehrig's disease. Story

> Roche has submitted its European application for vismodegib, a new treatment for advanced basal cell carcinoma. Roche release

> PTC Therapeutics has banked a $5 million discovery grant from the Wellcome Trust to support its work on a new antibiotic. Release

> Transcept Pharmaceuticals has received a $10 million milestone payment from Purdue Pharma in connection with the listing of Intermezzo formulation patents in the FDA Orange Book. Release

Pharma News

 @FiercePharma: Actavis CEO says generics biz "as we know it" is doomed as company launches branded pain drug in U.S. Release | Follow@FiercePharma

> U.S. officials seek execution drugs in India. Report

> Eyeing diagnostics growth, Roche up for $3B deal. Story

> Actavis CEO: Today's generics business is doomed. Item

> SC judge upholds $327M fine in Risperdal 'doctor letter' case. News

> J&J pulls 12M Motrin bottles as recalls lawsuit gets green light. Report

Vaccines News

> Pfizer, GSK to provide more discount vaccines for GAVI. Story

> Oxford researchers find malaria vaccine target. Article

> Canadian researcher gets FDA ok for HIV vaccine trial. Report

> Sanofi to relaunch Shan5 in 2013. Story

Manufacturing News

> FDA cites Akzo for contamination, leaky equipment. News

> Counterfeiter with Chinese connections is busted. Story

> Daiichi grimaces at Ranbaxy, FDA consent decree. Report

> Trout forges ahead on Novartis-MIT continuous processing effort. Article

And Finally... Editors at two prominent science publications are considering a "model" arrangement under which they may print part of the new research on a more lethal variety of bird flu and hold sensitive sections in a special repository that could only be accessed by "legitimate" scientists. An advisory panel has voiced concerns that terrorists could use the information to make a lethal virus capable of triggering a worldwide pandemic. Story

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.